KR20100022044A - 면역 조절제 화합물을 이용한 알레르기성 질환의 치료 방법 - Google Patents
면역 조절제 화합물을 이용한 알레르기성 질환의 치료 방법 Download PDFInfo
- Publication number
- KR20100022044A KR20100022044A KR1020097026139A KR20097026139A KR20100022044A KR 20100022044 A KR20100022044 A KR 20100022044A KR 1020097026139 A KR1020097026139 A KR 1020097026139A KR 20097026139 A KR20097026139 A KR 20097026139A KR 20100022044 A KR20100022044 A KR 20100022044A
- Authority
- KR
- South Korea
- Prior art keywords
- scv
- ova
- animals
- treatment
- asthma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 36
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 31
- 238000011282 treatment Methods 0.000 title claims description 57
- 239000002955 immunomodulating agent Substances 0.000 title 1
- 230000002584 immunomodulator Effects 0.000 title 1
- 229940121354 immunomodulator Drugs 0.000 title 1
- 230000000694 effects Effects 0.000 claims abstract description 28
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 6
- 125000003118 aryl group Chemical group 0.000 claims abstract description 5
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 claims abstract description 4
- 108010049353 golotimod Proteins 0.000 claims description 133
- CATMPQFFVNKDEY-YPMHNXCESA-N Golotimod Chemical compound C1=CC=C2C(C[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(O)=O)=CNC2=C1 CATMPQFFVNKDEY-YPMHNXCESA-N 0.000 claims description 130
- 208000006673 asthma Diseases 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 33
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- -1 heterocyclic amino acid Chemical group 0.000 claims description 5
- 229960004799 tryptophan Drugs 0.000 claims description 5
- 206010003645 Atopy Diseases 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-Tryptophan Natural products C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 102000007079 Peptide Fragments Human genes 0.000 claims description 3
- 108010033276 Peptide Fragments Chemical group 0.000 claims description 3
- 150000001412 amines Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical group C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 2
- 229930182827 D-tryptophan Chemical group 0.000 claims 1
- 101710188315 Protein X Chemical group 0.000 claims 1
- 239000000644 isotonic solution Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 9
- 108010016626 Dipeptides Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 82
- 210000004027 cell Anatomy 0.000 description 52
- 210000004072 lung Anatomy 0.000 description 47
- 239000002953 phosphate buffered saline Substances 0.000 description 41
- 239000013566 allergen Substances 0.000 description 30
- 238000012360 testing method Methods 0.000 description 30
- 210000003979 eosinophil Anatomy 0.000 description 28
- 239000000443 aerosol Substances 0.000 description 23
- 206010020751 Hypersensitivity Diseases 0.000 description 22
- 241000700198 Cavia Species 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 230000008595 infiltration Effects 0.000 description 16
- 238000001764 infiltration Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 210000000440 neutrophil Anatomy 0.000 description 16
- 206010011224 Cough Diseases 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 210000003743 erythrocyte Anatomy 0.000 description 14
- 230000000172 allergic effect Effects 0.000 description 13
- 208000010668 atopic eczema Diseases 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 12
- 102000044708 Eosinophil peroxidases Human genes 0.000 description 12
- 102000003896 Myeloperoxidases Human genes 0.000 description 12
- 108090000235 Myeloperoxidases Proteins 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000035515 penetration Effects 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 210000004969 inflammatory cell Anatomy 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 208000000059 Dyspnea Diseases 0.000 description 9
- 206010013975 Dyspnoeas Diseases 0.000 description 9
- 230000007815 allergy Effects 0.000 description 9
- 239000000739 antihistaminic agent Substances 0.000 description 9
- 210000000621 bronchi Anatomy 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 230000029058 respiratory gaseous exchange Effects 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 108010058846 Ovalbumin Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 238000011554 guinea pig model Methods 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 229940092253 ovalbumin Drugs 0.000 description 8
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 102000003810 Interleukin-18 Human genes 0.000 description 7
- 108090000171 Interleukin-18 Proteins 0.000 description 7
- 206010070834 Sensitisation Diseases 0.000 description 7
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 7
- 201000009961 allergic asthma Diseases 0.000 description 7
- 230000001387 anti-histamine Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000008313 sensitization Effects 0.000 description 7
- 208000013220 shortness of breath Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 210000002175 goblet cell Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 238000012387 aerosolization Methods 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 230000005713 exacerbation Effects 0.000 description 5
- 229940028885 interleukin-4 Drugs 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 231100000516 lung damage Toxicity 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 206010014950 Eosinophilia Diseases 0.000 description 4
- 208000004852 Lung Injury Diseases 0.000 description 4
- 206010069363 Traumatic lung injury Diseases 0.000 description 4
- 229960004784 allergens Drugs 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000428 dust Substances 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 231100000515 lung injury Toxicity 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000006199 nebulizer Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229960005205 prednisolone Drugs 0.000 description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000001932 seasonal effect Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 108010062580 Concanavalin A Proteins 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 241001440840 Mikania micrantha Species 0.000 description 3
- 206010028735 Nasal congestion Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000012754 cardiac puncture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 230000004073 interleukin-2 production Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000003562 morphometric effect Effects 0.000 description 2
- 238000013425 morphometry Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 1
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 239000010267 Allergoid Substances 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 240000009226 Corylus americana Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 244000195452 Wasabia japonica Species 0.000 description 1
- 235000000760 Wasabia japonica Nutrition 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000037446 allergic sensitization Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940127225 asthma medication Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 125000003164 beta-aspartyl group Chemical group 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000001813 broncholytic effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 1
- 108010054509 gamma-glutamyltryptophan Proteins 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 231100000824 inhalation exposure Toxicity 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000014828 interferon-gamma production Effects 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000010352 nasal breathing Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229940003691 nasonex Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 230000010152 pollination Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 229940018203 pyrilamine maleate Drugs 0.000 description 1
- 229940127558 rescue medication Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 229940090585 serevent Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940046536 tree pollen allergenic extract Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940070384 ventolin Drugs 0.000 description 1
- 229940063674 voltaren Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2007118237/14A RU2007118237A (ru) | 2007-05-17 | 2007-05-17 | Способ лечения аллергических заболеваний |
| RU2007118237 | 2007-05-17 | ||
| US95720107P | 2007-08-22 | 2007-08-22 | |
| US60/957,201 | 2007-08-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20100022044A true KR20100022044A (ko) | 2010-02-26 |
Family
ID=40122024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097026139A Withdrawn KR20100022044A (ko) | 2007-05-17 | 2008-05-13 | 면역 조절제 화합물을 이용한 알레르기성 질환의 치료 방법 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20100204295A1 (https=) |
| EP (1) | EP2164507B1 (https=) |
| JP (1) | JP2010527354A (https=) |
| KR (1) | KR20100022044A (https=) |
| CN (1) | CN101678069A (https=) |
| AU (1) | AU2008253667A1 (https=) |
| BR (1) | BRPI0811572A2 (https=) |
| CA (1) | CA2684046A1 (https=) |
| IL (1) | IL202114A0 (https=) |
| MX (1) | MX2009012297A (https=) |
| NZ (1) | NZ581748A (https=) |
| RU (1) | RU2007118237A (https=) |
| UA (1) | UA100018C2 (https=) |
| WO (1) | WO2008143824A1 (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200055218A (ko) * | 2018-11-12 | 2020-05-21 | 씨제이제일제당 (주) | N-아세틸-l-트립토판을 유효성분으로 포함하는 젖소용 사료첨가제 |
| KR20200135208A (ko) * | 2019-05-24 | 2020-12-02 | 전북대학교산학협력단 | N-아실-아미노산을 유효성분으로 포함하는 천식, 비염 또는 결막염의 예방 또는 치료용 조성물 |
| WO2020242133A1 (ko) * | 2019-05-24 | 2020-12-03 | 전북대학교 산학협력단 | N-아실-아미노산을 유효성분으로 포함하는 천식, 비염 또는 결막염의 예방 또는 치료용 조성물 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090119897A (ko) * | 2007-02-13 | 2009-11-20 | 사이클론 파아머슈티컬 인코오퍼레이티드 | 점막의 질환으로 인한 조직 악화, 상처 또는 손상을 치료 또는 예방하는 방법 |
| RU2635968C1 (ru) * | 2016-11-17 | 2017-11-17 | Аллан Герович Бениашвили | Способ лечения и профилактики состояний аллергического спектра |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728680A (en) * | 1987-12-30 | 1998-03-17 | Cytoven J.V. | Methods for normalizing numbers of lymphocytes |
| SU1544438A1 (ru) | 1988-04-04 | 1990-02-23 | Научно-исследовательский институт онкологии им.проф.Н.Н.Петрова | Способ плазмосорбции |
| US5032593A (en) * | 1988-07-01 | 1991-07-16 | Marion Merrell Dow Inc. | Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines |
| US5811399A (en) * | 1988-12-14 | 1998-09-22 | Cytran, Inc. | Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants |
| US5916878A (en) * | 1995-11-28 | 1999-06-29 | Edward T. Wei | γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith |
| US5744452A (en) * | 1995-11-28 | 1998-04-28 | Edward T. Wei | γ-L-glutamyl containing immunomodulator compounds and methods therewith |
| US7173013B2 (en) * | 2001-06-08 | 2007-02-06 | Sciclone Pharmaceuticals, Inc. | Treatment of tuberculosis using immunomodulator compounds |
| UA92586C2 (ru) * | 2004-05-14 | 2010-11-25 | Сайклон Фармасютикалс, Инк. | Лечение или предотвращение респираторных вирусных инфекций с помощью иммуномодуляторов |
-
2007
- 2007-05-17 RU RU2007118237/14A patent/RU2007118237A/ru unknown
-
2008
- 2008-05-13 WO PCT/US2008/006072 patent/WO2008143824A1/en not_active Ceased
- 2008-05-13 UA UAA200912624A patent/UA100018C2/ru unknown
- 2008-05-13 NZ NZ581748A patent/NZ581748A/en not_active IP Right Cessation
- 2008-05-13 JP JP2010508389A patent/JP2010527354A/ja not_active Ceased
- 2008-05-13 US US12/600,584 patent/US20100204295A1/en not_active Abandoned
- 2008-05-13 AU AU2008253667A patent/AU2008253667A1/en not_active Abandoned
- 2008-05-13 CA CA2684046A patent/CA2684046A1/en not_active Abandoned
- 2008-05-13 MX MX2009012297A patent/MX2009012297A/es not_active Application Discontinuation
- 2008-05-13 KR KR1020097026139A patent/KR20100022044A/ko not_active Withdrawn
- 2008-05-13 BR BRPI0811572-9A patent/BRPI0811572A2/pt not_active IP Right Cessation
- 2008-05-13 EP EP08825917A patent/EP2164507B1/en active Active
- 2008-05-13 CN CN200880016455A patent/CN101678069A/zh active Pending
-
2009
- 2009-11-12 IL IL202114A patent/IL202114A0/en unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200055218A (ko) * | 2018-11-12 | 2020-05-21 | 씨제이제일제당 (주) | N-아세틸-l-트립토판을 유효성분으로 포함하는 젖소용 사료첨가제 |
| KR20200135208A (ko) * | 2019-05-24 | 2020-12-02 | 전북대학교산학협력단 | N-아실-아미노산을 유효성분으로 포함하는 천식, 비염 또는 결막염의 예방 또는 치료용 조성물 |
| WO2020242133A1 (ko) * | 2019-05-24 | 2020-12-03 | 전북대학교 산학협력단 | N-아실-아미노산을 유효성분으로 포함하는 천식, 비염 또는 결막염의 예방 또는 치료용 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| UA100018C2 (ru) | 2012-11-12 |
| IL202114A0 (en) | 2010-06-16 |
| CA2684046A1 (en) | 2008-11-27 |
| EP2164507B1 (en) | 2012-07-11 |
| NZ581748A (en) | 2012-03-30 |
| EP2164507A4 (en) | 2011-01-05 |
| BRPI0811572A2 (pt) | 2015-07-21 |
| RU2007118237A (ru) | 2008-11-27 |
| AU2008253667A1 (en) | 2008-11-27 |
| WO2008143824A1 (en) | 2008-11-27 |
| MX2009012297A (es) | 2010-02-17 |
| EP2164507A1 (en) | 2010-03-24 |
| CN101678069A (zh) | 2010-03-24 |
| JP2010527354A (ja) | 2010-08-12 |
| US20100204295A1 (en) | 2010-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4536918B2 (ja) | 免疫調整機能を有するγ−グルタミルとβ−アスパルチル化合物および免疫調節剤 | |
| EP2969010B1 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
| US8975294B2 (en) | Desferrioxamine-metal complexes for the treatment of immune-related disorders | |
| JP2002509074A (ja) | 熱ショックタンパク質を使用する、炎症性疾患を処置する方法 | |
| US9421248B2 (en) | Alpha 1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations | |
| KR20100022044A (ko) | 면역 조절제 화합물을 이용한 알레르기성 질환의 치료 방법 | |
| ES2378076T3 (es) | Métodos para la inhibición de células NKT | |
| JPH0222733B2 (https=) | ||
| WO2009154800A2 (en) | Compositions and methods for treating lung disorders | |
| US20080051333A1 (en) | Human alpha-defensins inhibit interleukin-1beta release | |
| US20070161541A1 (en) | Insult induced immune dissonance | |
| WO2023110855A1 (en) | Compositions for treating autoimmune arthritis | |
| US20080306079A1 (en) | External preparation for allergic diseases | |
| US20080311103A1 (en) | Anti-Inflammatory Peptides and Methods of Use Thereof | |
| HK1142534A (en) | Treatment of allergic disease with immunomodulator compounds | |
| JP2025505538A (ja) | アレルギー性喘息の治療および／または予防のためのスーパーオキシドジスムターゼの使用 | |
| EP3157542B1 (en) | Methods to treat inflammation of the lung | |
| US20230127198A1 (en) | Compositions and methods for the treatment of toxic gas exposure | |
| EP1569631B1 (en) | A method of preventing and/or treating asthma using parabromophenacyl bromide (pbpb) | |
| Buhl | EVS1-3 New treatment approach to severe allergic asthma: Real life study in Germany | |
| Kale et al. | Therapeutics for Allergy Management | |
| WO1999056744A1 (en) | Immunosuppressant containing glucopyranose derivative as active ingredient | |
| Kim et al. | Indoor Dust Derived Extracellular Vesicles Induce Chronic Lung Inflammatory Diseases Mediated By Th17 Immune Response | |
| JPWO2000003734A1 (ja) | アレルギー疾患治療剤 | |
| NZ621596B2 (en) | Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20091215 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |